Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 1(1)

Loading network data...

Showing 4 of 4 trials

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Role: collaborator

Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet

Role: collaborator

Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy

Role: collaborator

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

Role: collaborator

All 4 trials loaded